Antidote Health, a New York-based telehealth platform offering integrated mental health, primary care, and other health services, has successfully raised $22 million in a Series A funding round. The round was led by seasoned investor iAngels, with participation from Group 11 and Flint Capital. This funding follows an earlier seed round of $12 million and marks a significant milestone for the company as it accelerates the growth and development of its AI-powered telehealth services platform.
Leveraging AI to Revolutionize Telehealth Services
Founded in 2020 and launched in January 2024, Antidote Health differentiates itself by integrating artificial intelligence to streamline administrative tasks traditionally burdening healthcare providers. This AI technology allows doctors and clinicians to focus more on patient care while ensuring the platform remains accessible 24/7 to users nationwide. The foundation of Antidote’s offerings is an enhanced evidence-based care model, a standard established by the American Psychiatric Association, which supports clinical precision and personalized patient treatment within its AI-powered telehealth services.
New Mental Health Services Expand Care Options
Earlier this month, Antidote expanded its portfolio by launching dedicated mental health services. This new offering connects users with licensed mental health clinicians who collaboratively develop personalized treatment plans. These plans can include prescription medications, which clinicians monitor and adjust based on patient progress and changing needs. Antidote’s mental health services address common conditions such as depression, anxiety, panic disorder, post-traumatic stress disorder (PTSD), and obsessive-compulsive disorder (OCD). These services are priced competitively, starting at $79 per month for regular plans, with enhanced plans available for $99. Importantly, mental health care is also offered as an optional supplement for users already subscribed to primary care or hypertension management plans, further enhancing the accessibility of Antidote’s AI-powered telehealth services.
Expanding Access and Rapid Growth
Antidote Health’s platform currently reaches approximately 60% of the U.S. population, reflecting its broad coverage and growing footprint. The company treats around 2,500 patients each month and has sustained an impressive 30% monthly growth rate. This rapid uptake is driven by the increasing demand for convenient, technology-enabled healthcare, particularly in the mental health sector. The company’s growth demonstrates how AI-powered telehealth services can meet patient needs more effectively by reducing barriers like geographic limitations and traditional appointment scheduling.
Strategic Investment to Boost AI and Clinical Capabilities
Shelly Hod Moyal, founding partner at iAngels, highlighted the significance of Antidote’s approach, describing it as a solution to critical inefficiencies in the $4 trillion healthcare market. The Series A funding will be invested heavily in research and development aimed at advancing Antidote’s AI capabilities. Planned improvements include more sophisticated AI screening tools and enhanced clinical decision support systems designed to improve diagnostic accuracy and treatment outcomes—core components that drive the success of Antidote’s AI-powered telehealth services.
Vision for Becoming a Digital Health Maintenance Organization
Looking ahead, Antidote Health aims to evolve into a digital health maintenance organization (HMO) that not only delivers care but also provides insurance coverage. This ambitious goal involves navigating complex regulatory landscapes to obtain necessary licenses and expanding the provider network nationwide. By combining insurance and services under one digital umbrella, Antidote envisions a streamlined, patient-centric healthcare experience fully supported by its AI-powered telehealth services platform.
Commitment to Affordable, Quality Healthcare
CEO Avihai Sodri expressed optimism about the company’s future, stating, “This Series A funding round will allow Antidote Health to help Americans in more ways than ever by adding chronic and primary care services backed by our innovative technology and amazing care teams.” Antidote’s mission centers on making high-quality healthcare affordable and accessible, leveraging AI-powered telehealth services to break down traditional barriers to care and improve patient outcomes.
The Growing Role of AI-Powered Telehealth Services in Healthcare
The COVID-19 pandemic accelerated adoption of telehealth, highlighting the need for scalable, flexible healthcare solutions. Antidote Health is at the forefront of this shift, using AI-powered telehealth services to deliver personalized, efficient care that adapts to patient needs. By integrating cutting-edge AI tools, the company enhances provider productivity and patient engagement alike, offering a more responsive and holistic healthcare experience.
Conclusion: Antidote Health is Shaping the Future of Telehealth
Antidote Health’s recent $22 million Series A funding round signals strong market confidence in the company’s vision and technology. Its AI-powered telehealth services platform continues to grow rapidly, serving thousands of patients across the U.S. with accessible mental health and primary care solutions. As Antidote works toward becoming a digital health maintenance organization, its innovative approach to integrating AI and telehealth sets a new standard for affordable, patient-centered care. This company is well-positioned to redefine healthcare delivery by making it more accessible, personalized, and technologically advanced than ever before.
